Reservoir-Based Polymer-Free Amphilimus-Eluting Stent Versus Polymer-Based Everolimus-Eluting Stent in Diabetic Patients (RESERVOIR) Trial

Trial Profile

Reservoir-Based Polymer-Free Amphilimus-Eluting Stent Versus Polymer-Based Everolimus-Eluting Stent in Diabetic Patients (RESERVOIR) Trial

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2015

At a glance

  • Drugs Sirolimus (Primary) ; Everolimus
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial infarction; Thrombosis; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms RESERVOIR
  • Most Recent Events

    • 02 Sep 2015 Results (n=101 lesions) presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology
    • 05 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 22 Aug 2013 Planned End Date changed from 1 Jan 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top